FDA approved votrient for advanced soft tissue sarcoma
-
Last Update: 2012-04-27
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of medicine 2012-04-27 US Food and Drug Administration today approved votrient (pazopanil) for the treatment of advanced soft tissue sarcoma patients who had received chemotherapy Soft tissue sarcoma is a kind of cancer in muscle, fat, fibrous tissue and other tissues Votrient is an oral preparation to inhibit the growth and survival of tumor Soft tissue sarcoma is a rare cancer with many subtypes There are about 10000 patients with soft tissue sarcoma in the United States every year More than 20 subtypes of soft tissue sarcoma were included in the clinical trials that led to the approval of votrient The drug was not approved for use in patients with lipocytic soft tissue sarcoma and gastrointestinal stromal tumor Original link: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
